Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

638681

registered interest
date	18/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 8 November 2016 to Question 51807, for what reasons access to the new treatments for hepatitis C that have been approved as cost-effective by NICE has been limited to 10,011 people in 2016-17.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	53772
answer	answer is ministerial correction date of answer 28/11/2016 answer text <p>The guidance issued by the National Institute for Health and Care Excellence (NICE) in relation to new direct acting antivirals for hepatitis C recommends that the decision to treat, and prescribing decisions, are made by multidisciplinary teams in the operational delivery networks put in place by NHS England. These prioritise treatment for people with the highest unmet clinical need.</p><p> </p><p>NHS England’s commitment to treat 10,000 patients in 2016/17, increasing to 12,500 in 2017/18, is in line with NICE’s estimate of activity included in the costing tools published to support implementation of the guidance.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 53767 question first answered 28/11/2016 15:17:26 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4433 label Biography information for Thangam Debbonaire

638682

registered interest
date	18/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS England on its decision to limit the number of people able to access new hepatitis C treatments to 10,011; and on what basis that number was chosen.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	53767
answer	answer is ministerial correction date of answer 28/11/2016 answer text <p>The guidance issued by the National Institute for Health and Care Excellence (NICE) in relation to new direct acting antivirals for hepatitis C recommends that the decision to treat, and prescribing decisions, are made by multidisciplinary teams in the operational delivery networks put in place by NHS England. These prioritise treatment for people with the highest unmet clinical need.</p><p> </p><p>NHS England’s commitment to treat 10,000 patients in 2016/17, increasing to 12,500 in 2017/18, is in line with NICE’s estimate of activity included in the costing tools published to support implementation of the guidance.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 53772 question first answered 28/11/2016 15:17:25 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4433 label Biography information for Thangam Debbonaire